Skip to main content
logo
Olympus Corporation (TYO:7733)
Japan flag Japan · Delayed Price · Currency is JPY
2,072.00
-13.50 (-0.65%)
At close: Jan 13, 2026

Revenue by Geography

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Japan Revenue
106.84B110.11B
Log In
Log In
Log In
Upgrade
North America Revenue
397.59B413.81B
Log In
Log In
Log In
Upgrade
Europe Revenue
258.15B254.62B
Log In
Log In
Log In
Upgrade
China Revenue
85.49B95.72B
Log In
Log In
Log In
Upgrade
Asia and Oceania Revenue (Post-FY2019 Reporting)
97.62B93.69B
Log In
Log In
Log In
Upgrade
Asia and Oceania Revenue (Pre-FY2020 Reporting)
183.11B189.41B
Log In
Log In
Log In
Upgrade
Other Countries Revenue
31.62B28.84B
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Endoscopic Solutions Division Revenue
636.14B
Log In
Log In
Log In
Upgrade
Therapeutic Solutions Division Revenue
360.66B
Log In
Log In
Log In
Upgrade
Total Medical Solutions Division Revenue
996.80B
Log In
Log In
Log In
Upgrade
Other Division Revenue (Post-FY2024 Reporting)
530.00M
Log In
Log In
Log In
Upgrade
Other Division Revenue (Pre-FY2025 Reporting)
-
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Gastrointestinal Solutions Division Revenue
658.66B674.04B
Log In
Log In
Log In
Upgrade
Surgical & Interventional Solutions Division Revenue
318.64B322.76B
Log In
Log In
Log In
Upgrade

EBIT

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Endoscopic Solutions Division Operating Profit
141.40B
Log In
Log In
Log In
Upgrade
Therapeutic Solutions Division Operating Profit
61.45B
Log In
Log In
Log In
Upgrade
Total Medical Solutions Division Operating Profit
202.85B
Log In
Log In
Log In
Upgrade
Other Division Operating Profit (Post-FY2024 Reporting)
-473.00M
Log In
Log In
Log In
Upgrade
Other Division Operating Profit (Pre-FY2025 Reporting)
-
Log In
Log In
Log In
Upgrade
Eliminations from Division Operating Profit
-39.92B
Log In
Log In
Log In
Upgrade

EBIT 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Sep '25 Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
Gastrointestinal Solutions Division Operating Profit
143.72B167.89B
Log In
Log In
Log In
Upgrade
Surgical & Interventional Solutions Division Operating Profit
8.24B14.69B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 20222012 - 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 2012 - 2021
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment
3.00%
Log In
Log In
Log In
Upgrade
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment
5.00%
Log In
Log In
Log In
Upgrade
ESD - Medical Service Revenue Growth Rate After FX Adjustment
5.00%
Log In
Log In
Log In
Upgrade
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment
4.00%
Log In
Log In
Log In
Upgrade
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment
2.00%
Log In
Log In
Log In
Upgrade
TSD - Urology Revenue Growth Rate After FX Adjustment
6.00%
Log In
Log In
Log In
Upgrade
TSD - Respiratory Revenue Growth Rate After FX Adjustment
10.00%
Log In
Log In
Log In
Upgrade
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment
-7.00%
Log In
Log In
Log In
Upgrade
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment
3.00%
Log In
Log In
Log In
Upgrade
Company's Total Revenue Growth Rate After FX Adjustment
-
Log In
Log In
Log In
Upgrade
Updated Sep 30, 2025. Data Source: Fiscal.ai.